Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is not typically a mucus-heavy disease in the way most people imagine. About 80% of IPF patients report a chronic dry cough rather than the wet, phlegmy cough associated with conditions like bronchitis or cystic fibrosis. Yet the relationship between pulmonary fibrosis and mucus turns out to be far more interesting than that straightforward clinical picture suggests, because a mucus-producing gene sits at the very center of what causes the disease in the first place.
Why the Cough Is Usually Dry
The hallmark respiratory symptom of IPF is a persistent, hacking cough that produces little to nothing. Studies consistently describe it as nonproductive, meaning no phlegm comes up. One review put the prevalence of chronic dry cough at roughly 80% of IPF patients, making it one of the most common and frustrating complaints people with the disease experience.1PubMed. The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis The cough tends to be triggered by deep breaths, talking, laughing, or changes in temperature, and it can be severe enough to interfere with sleep, conversation, and daily life.
The reason the cough is dry has to do with where pulmonary fibrosis does its damage. The scarring happens deep in the lung tissue, in and around the tiny air sacs (alveoli) where gas exchange takes place, not primarily in the large airways where mucus-producing glands are concentrated. Because the main battleground is the lung’s scaffolding rather than its airways, the disease irritates cough receptors through mechanical distortion of the tissue rather than through mucus overload. The lungs stiffen and shrink as scar tissue builds up, and that distortion alone is enough to trigger persistent coughing.
When Mucus Does Show Up
That said, “usually dry” is not “always dry.” A meaningful subset of people with IPF do cough up sputum, and recent research has started paying closer attention to this group. One cross-sectional study found that productive cough in IPF is more common than traditionally acknowledged and that it meaningfully affects quality of life. Patients with productive cough tended to have worse patient-reported outcomes and reduced normal lung volume on imaging.2PubMed Central. Productive cough associated with patient-reported outcomes and computed tomography analysis results in idiopathic pulmonary fibrosis: a single centre cross-sectional study
Several things can explain mucus production in someone with pulmonary fibrosis. As IPF advances, the scarring can distort and widen the small airways, creating a condition called traction bronchiectasis. Those damaged, stretched-out airways lose their ability to clear secretions normally, and mucus pools in them. A review in the European Respiratory Review noted that when sputum does appear in IPF, it is often nonpurulent (clear or white rather than green or yellow) and may be linked to traction bronchiectasis or to coexisting chronic obstructive pulmonary disease.3European Respiratory Review. Cough in idiopathic pulmonary fibrosis The sputum, in other words, is a consequence of structural damage to the airways rather than the kind of infection-driven mucus overproduction you see in pneumonia or acute bronchitis.
Interestingly, when researchers directly compared how much sputum IPF patients produce against people with chronic cough from other causes, the two groups scored almost identically on a validated cough questionnaire. A case-control study using the Leicester Cough Questionnaire found no significant difference in sputum frequency between IPF patients with chronic cough and a community-based chronic cough population.4PubMed Central. Characteristics of idiopathic pulmonary fibrosis-associated cough: a case-control study That finding suggests the sputum component of IPF cough, when present, is not dramatically different from what you would see in other chronic cough conditions.
The MUC5B Paradox
Here is where the story gets genuinely surprising. The single strongest known risk factor for developing IPF is not an environmental exposure or an immune system glitch. It is a variant in the promoter region of a gene called MUC5B, which encodes one of the major gel-forming mucins in human airways. A landmark study in the New England Journal of Medicine found that people carrying one copy of this variant had roughly nine times the odds of developing IPF compared to noncarriers, and those with two copies had about 22 times the odds.5PubMed Central. A common MUC5B promoter polymorphism and pulmonary fibrosis No other genetic variant comes close to that effect size for this disease.
What the variant does, essentially, is crank up production of MUC5B protein. In the lungs of people with IPF, MUC5B is overexpressed in the small airways and in the honeycomb cysts that form as the disease progresses.6PubMed Central. MUC5B and Idiopathic Pulmonary Fibrosis The MUC5B promoter variant accounts for at least 30% of the total risk of developing IPF, and it has been replicated in multiple independent cohorts, which is unusual for a single genetic variant in a complex disease.7PubMed Central. Idiopathic Pulmonary Fibrosis Is a Genetic Disease Involving Mucus and the Peripheral Airways
So there is a genuine paradox at the heart of IPF: the disease that gives people a dry cough is genetically driven by a mucus gene turned up too high. The excess MUC5B does not end up being coughed out as productive sputum in most patients. Instead, researchers believe it accumulates in the small peripheral airways and the damaged honeycomb regions of the lung, where it may contribute to ongoing injury. The mucus is there; it is just deep in the lung rather than in the large airways where you would feel it as phlegm. Histological studies of IPF lungs have confirmed that the mucus cells lining the remodeled distal airspaces predominantly express MUC5B, with low levels of MUC5AC, which is the mucin usually responsible for the thick sputum people associate with conditions like asthma.8Thorax. Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis
How Excess Mucus May Drive the Scarring
Understanding MUC5B’s role has shifted how some researchers think about the disease. Rather than viewing IPF purely as a problem of wound healing gone wrong in the alveoli, a growing body of evidence points to the peripheral airways, the tiny tubes feeding into the air sacs, as an important site where the disease starts. Abnormal mucus buildup in these small airways may impair the lungs’ ability to clear inhaled particles and pathogens, creating a cycle of low-grade injury and abnormal repair that eventually leads to fibrosis.
A review in Physiological Reviews laid out the hypothesis that excessive MUC5B production either worsens injury by reducing mucociliary clearance or interferes with the lung’s normal repair mechanisms in the distal airways.9PubMed Central. Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways In animal experiments, mice engineered to overexpress MUC5B showed disrupted ciliary beat frequency and reduced mucociliary transport rates, meaning the tiny hair-like structures that sweep mucus up and out of the lungs could not do their job properly.10Nature Communications. Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice These mice also developed more severe fibrosis when exposed to a lung-scarring agent, suggesting that mucus dysfunction is not just a bystander but an active contributor to the scarring process.
On top of the mucus problem, IPF lungs show abnormalities in the cilia themselves. Research has found that the distal airways in IPF tissue have increased numbers of ciliated cells, but those cilia have structural defects that compromise their function.11PubMed Central. Aberrant Multiciliogenesis in Pulmonary Fibrosis: Bystander or Driver of Disease Progression? So the system breaks down on both sides: too much of the wrong mucus in the wrong place, and dysfunctional cilia that cannot clear it. The result is a lung environment where debris, microbes, and inflammatory signals linger longer than they should, perpetuating injury and fibrotic remodeling.
The Role of Silent Reflux
Another route by which unwanted material ends up in fibrotic lungs is gastroesophageal reflux. An estimated 90% of IPF patients have abnormal acid reflux on 24-hour monitoring, and in most cases it is “silent,” meaning they have no heartburn or other classic symptoms.12European Respiratory Journal. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? The concern is microaspiration: tiny amounts of stomach contents repeatedly seeping into the lower airways, particularly during sleep. This chronic, low-level chemical irritation can trigger inflammatory responses and stimulate mucus production in the airways, compounding whatever mucus-related dysfunction is already happening from the MUC5B overexpression.
Whether treating reflux actually slows IPF progression remains uncertain and is an active area of study, but the sheer prevalence of silent reflux in this population suggests it is at least part of the symptom picture. For patients who do notice increased sputum, particularly in the morning, microaspiration is worth discussing with a pulmonologist because it represents a potentially modifiable contributor.
Mucins as Biomarkers
The mucin connection in IPF extends beyond MUC5B. Researchers have been investigating several mucin proteins as potential biomarkers for tracking disease activity. KL-6, which is a form of MUC1, tends to be elevated in the blood of IPF patients, and levels rise further during acute exacerbations, the sudden and dangerous flare-ups that can rapidly worsen the disease. MUC1 and MUC4 have also been found to be overexpressed in the main cell types involved in IPF.13PubMed Central. Mucins as a New Frontier in Pulmonary Fibrosis The hope is that tracking mucin levels in blood could eventually help clinicians detect worsening disease earlier than current lung function tests do, or identify which patients are at highest risk for exacerbations.
The airway epithelial cells lining the remodeled regions of IPF lungs are themselves abnormal, having undergone changes that make them resemble cells from larger airways or even glandular tissue rather than the delicate alveolar lining they should be. Single-cell RNA sequencing studies have documented these shifts in cell identity and signaling, suggesting that the epithelium in IPF is not just scarred but fundamentally reprogrammed.14PubMed Central. Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis Mucus-producing cells appearing where they do not belong is one visible consequence of that reprogramming.
What About Mucolytic Treatments
Given the central role of mucus biology in IPF, it is natural to wonder whether drugs that thin or reduce mucus might help. N-acetylcysteine (NAC), a mucolytic and antioxidant available over the counter in many countries, has been studied in IPF for decades with frustratingly mixed results. An earlier trial reported that high-dose NAC, added to a standard treatment regimen, slowed the decline in lung function measures over 12 months compared to placebo.15PubMed. High-dose acetylcysteine in idiopathic pulmonary fibrosis A later systematic review and meta-analysis also found that NAC therapy appeared to reduce the decline in lung function with an acceptable safety profile.16PubMed Central. Efficacy and safety of N-acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and meta-analysis
However, the most rigorous trial, the PANTHER-IPF study, threw cold water on the idea. When NAC was tested as a standalone treatment against placebo in patients with mild-to-moderate IPF, there was no significant difference in the change in lung capacity between the two groups over 60 weeks.17PubMed Central. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis Rates of death and acute exacerbation were also similar. The discrepancy between the earlier positive signals and this definitive negative result likely reflects differences in study design and patient populations. As a result, NAC is not recommended as a primary treatment for IPF in current guidelines, though some patients and clinicians still use it as a supplementary measure.
The two drugs that are approved for IPF, pirfenidone and nintedanib, work through anti-fibrotic and anti-inflammatory mechanisms rather than by targeting mucus directly. Neither drug is a mucolytic. They slow the rate of lung function decline but do not cure the disease or specifically address mucus-related symptoms. For patients troubled by productive cough, conventional airway clearance techniques and adequate hydration remain the standard supportive measures, though the evidence for these specifically in IPF (as opposed to diseases like bronchiectasis or COPD) is thin.
How IPF Mucus Differs From Other Lung Diseases
If you or someone you know has pulmonary fibrosis and produces sputum, it is worth understanding how it differs from what happens in other chronic lung conditions. In COPD or chronic bronchitis, mucus hypersecretion is a primary feature: the large airways overproduce mucus in response to years of irritation from smoking or pollution, and patients cough up significant volumes daily. In cystic fibrosis, a genetic defect in chloride channels makes airway mucus extremely thick and sticky, leading to chronic infection. In asthma, MUC5AC overproduction creates the characteristic thick, rubbery mucus plugs that narrow the airways during attacks.
IPF is different on virtually every count. The mucus problem is dominated by MUC5B rather than MUC5AC. The overproduction happens in the peripheral airways and honeycomb cysts rather than in the central airways. And the sputum that patients produce, when they produce any, tends to be scanty and clear rather than copious or colored. Even at the molecular level, the inflammatory profile in IPF sputum is distinct from COPD sputum. One study found that despite similar cellular patterns in induced sputum from COPD and IPF patients, there were marked differences in the balance of tissue-remodeling enzymes.18PubMed. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects
For patients, the practical upshot is that strategies designed for mucus-heavy diseases, such as aggressive nebulized saline treatments or high-frequency chest wall oscillation devices, are not automatically appropriate for IPF. These approaches are well-studied in conditions like cystic fibrosis and bronchiectasis but have limited evidence behind them for pulmonary fibrosis specifically. If mucus is a significant problem, it is worth having a conversation with a pulmonologist about whether an underlying complication like traction bronchiectasis or reflux-related aspiration might explain it, because the treatment approach depends on the cause.
When to Be Concerned About a Change in Sputum
For someone living with IPF, a shift from a dry cough to a productive one, or a change in the color or volume of sputum, deserves medical attention. Green or yellow sputum often signals a respiratory infection, which can trigger acute exacerbations of IPF, some of the most dangerous episodes in the disease course. Increased sputum volume without obvious infection could indicate worsening traction bronchiectasis, progression of the disease, or a new complication like aspiration. Even blood-tinged sputum, while alarming, is occasionally seen in IPF and can result from the fragile, abnormal blood vessels in scarred lung tissue.
Keeping a rough log of cough characteristics, whether it is dry or wet, how much sputum comes up, and what it looks like, gives your care team useful information at follow-up visits. These details, combined with lung function tests and imaging, help clinicians piece together whether the disease is stable, slowly progressing, or headed toward a complication that needs intervention.